All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

Recombinant Human 5'-nucleotidase (NT5E) (Active)

In Stock
Code CSB-MP723415HU
Abbreviation Recombinant Human NT5E protein (Active)
MSDS
MSDS Datasheet
Size $138
Order now
Image
  • CSB-MP723415HU SDS-page
    (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
  • CSB-MP723415HU Activity assay 01
    Activity
    Measured by its binding ability in a functional ELISA. Immobilized CD73 at 2 μg/ml can bind Anti- CD73 Rabbit Monoclonal Antibody(CSB-RA978310A0HU), the EC50 is 3.212-4.525 ng/ml. Biological Activity Assay
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
Greater than 95% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU/ug as determined by LAL method.
Activity
Measured by its binding ability in a functional ELISA. Immobilized CD73 at 2 μg/ml can bind Anti- CD73 Rabbit Monoclonal Antibody(CSB-RA978310A0HU), the EC50 is 3.212-4.525 ng/ml.
Target Names
NT5E
Uniprot No.
P21589
Alternative Names
(5'-NT)(Ecto-5'-nucleotidase)(CD73)(NT5)(NTE)
Molecular Characterization
Species
Homo sapiens (Human)
Source
Mammalian cell
Expression Region
27-549aa
Target Protein Sequence
WELTILHTNDVHSRLEQTSEDSSKCVNASRCMGGVARLFTKVQQIRRAEPNVLLLDAGDQYQGTIWFTVYKGAEVAHFMNALRYDAMALGNHEFDNGVEGLIEPLLKEAKFPILSANIKAKGPLASQISGLYLPYKVLPVGDEVVGIVGYTSKETPFLSNPGTNLVFEDEITALQPEVDKLKTLNVNKIIALGHSGFEMDKLIAQKVRGVDVVVGGHSNTFLYTGNPPSKEVPAGKYPFIVTSDDGRKVPVVQAYAFGKYLGYLKIEFDERGNVISSHGNPILLNSSIPEDPSIKADINKWRIKLDNYSTQELGKTIVYLDGSSQSCRFRECNMGNLICDAMINNNLRHTDEMFWNHVSMCILNGGGIRSPIDERNNGTITWENLAAVLPFGGTFDLVQLKGSTLKKAFEHSVHRYGQSTGEFLQVGGIHVVYDLSRKPGDRVVKLDVLCTKCRVPSYDPLKMDEVYKVILPNFLANGGDGFQMIKDELLRHDSGDQDINVVSTYISKMKVIYPAVEGRIKFS
Mol. Weight
60.2 kDa
Protein Length
Full Length of Mature Protein
Tag Info
C-terminal 6xHis-tagged
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer
Lyophilized from a 0.2 μm filtered 20 mM Tris-HCl, 0.5 M NaCl, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Protein FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
3-7 business days
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA
Please contact us to get it.
Description

CD73 (NT5E) serves as a critical ectoenzyme in purinergic signaling, hydrolyzing extracellular AMP to adenosine and thereby modulating immune responses within the tumor microenvironment. This recombinant human CD73 encompasses the full mature protein (aa 27–549) expressed in mammalian cells with a C-terminal 6×His tag, positioning the tag away from the catalytic domain to preserve native enzymatic function. Binding activity has been confirmed by functional ELISA, where immobilized CD73 at 2 μg/mL bound an anti-CD73 monoclonal antibody with an EC50 of 3.212–4.525 ng/mL, supporting its use as a positive control in enzyme-linked assays, inhibitor screening for IC50 determination, and kinetic parameter analysis (Km, Vmax, kcat). Purity exceeding 95% by SDS-PAGE combined with endotoxin levels below 1.0 EU/μg satisfies the criteria typically required for accurate specific activity measurements, substrate specificity profiling, and drug candidate evaluation studies targeting adenosinergic pathways.

Related Products

NT5E Antibodies

NT5E Proteins

NT5E ELISA kits

Customer Reviews and Q&A

■ Customer Reviews
Average Rating:
5.0 - 1 reviews

Submit a Review here

Applications : Cell culture-serum-free medium

Review: I used the CSB-MP723415HU product for an ELISA experiment, and the EC50 was measured to be 5.809-7.175 ng/ml. The protein showed good binding activity. It has stable properties and good repeatability, and the experimental progress is smooth. As a result, I plan to continue large-scale procurement in the future.

By Anonymous

Read more reviews >>

Target Background

Function
Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
Gene References into Functions
  1. Changes in the local expression and activity of CD39 and CD73 in calcified valves suggest their potential role in calcific aortic valve disease. PMID: 30056298
  2. High expression of NT5E is associated with Prostate Cancer. PMID: 29916747
  3. Case Report: identify novel mutations in the NT5E gene in patient with calcification of joints and arteries. PMID: 28825389
  4. High CD73 expression is associated with breast cancer. PMID: 29047106
  5. High CD73 expression is associated with neoplasms. PMID: 29514610
  6. NT5E-targeting miRNAs (miR-30b and miR-340) function as tumor suppressors PMID: 29155108
  7. soluble CD73 might be used as serologic prognostic biomarker in patients with metastatic melanoma patients. PMID: 29202855
  8. High CD73 expression is associated with the increase in the ability of surviving breast cancer cells to evade innate and adaptive immunity. PMID: 29367423
  9. analysis of how inhibitors block human CD73 and block efficiently its enzymatic function in the low micromolar range through a non-competitive inhibition mechanism PMID: 29377887
  10. The Ecto-5'nucleotidase, together with alkaline phosphatase, also expressed apically in oviductal epithelium, complete the hydrolysis sequence by dephosphorylating AMP to adenosine. PMID: 29273916
  11. this paper shows that simultaneous overexpression of human E5NT and ENTPD1 protects porcine endothelial cells against H2O2-induced oxidative stress and cytotoxicity in vitro PMID: 28389406
  12. high levels of CD73 are significantly associated with reduced overall survival in patients with head and neck squamous cell carcinoma PMID: 27557512
  13. Studied role of miR-30a in colorectal cancer(CRC). Found miR-30a is downregulated in CRC, and it inhibits cell proliferation in CRC by reducing expression of CD73. PMID: 28464916
  14. we demonstrated the existence of CSCs in both cultured ccRCC cell line and tissues, and CD73 as a cell-surface biomarker for ccRCC CSC-like cells. PMID: 28404888
  15. Induction of ecto-5'-nucleotidase/CD73 by radiation contributes to the radiosensitivity of T24 urinary bladder cancer cell line. PMID: 29305710
  16. Report prognostic impact of CD73 expression in non-small lung cancers. PMID: 28060732
  17. Data show that MiR-422a and its target CD73 are involved in early loco(regional) recurrence of head and neck squamous cell carcinoma (HNSCC) tumors and are targets for personalized medicine. PMID: 27281619
  18. HPV+ cervical cancer cells express higher levels of CD73 than HPV- cells, and this expression is associated with the production of larger amounts of adenosine, as well as a stronger inhibition of proliferation, activation, and cytotoxic activity of CD8+ T cells via interaction with A2A adenosine receptor PMID: 28950987
  19. High CD73 expression is associated with Melanoma Metastasis. PMID: 28652244
  20. Hippocampal astrogliosis observed in medial temporal lobe epilepsy patients was accompanied by a proportionate increase in A2A receptor and ecto-5'-nucleotidase/CD73 immunoreactivities. PMID: 27650530
  21. High CD73 expression is associated with cervical cancer. PMID: 28202050
  22. Endogenous Plastic Somatic (ePS) cells in a latent state, i.e. lacking SOX2, OCT3/4 and NANOG (SON) expression, in non-diseased breast specimens through immunohistochemical analysis of previously identified ePS-specific biomarkers (CD73(+), EpCAM(+) and CD90(-)). PMID: 27705752
  23. Down-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression. PMID: 28193736
  24. CD73 polymorphisms play a role in calciphylaxis development in dialysis patients. PMID: 28212442
  25. CD73 expression is upregulated in NSCLC and is correlated with a decrease in miR-30a-5p expression. PMID: 28158983
  26. This study found that in septic critically ill patients the soluble CD73 levels were generally low and showed a further decrease from 0h to 24h. Moreover, the sCD73 levels were higher in acute kidney injury (AKI) versus non-AKI patients and in non-survivors with severe sepsis than in survivors, but were not independently associated either with the development of AKI or 90-day mortal PMID: 27732656
  27. concluded that CD39 and CD73 are molecular targets for the development of drugs for ALF patients care PMID: 27899277
  28. Genetic polymorphism of NT5E may contribute to the pathogenesis of calcific aortic valve disease. PMID: 27906615
  29. Oxidized low density lipoproteins modulate CD39 and CD73 activity in the endothelium. PMID: 27906627
  30. CD73 may play an important role in breast cancer stem cells. PMID: 27670764
  31. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface as well as CD39 and CD73 expressions on platelets of sickle cell anemia treated patients. PMID: 27044834
  32. Aim of the present study was to investigate the role of CD73 in glioma blood vessels; results found that the expression of CD73 in glioma vascular cells is significantly decreased, and this reduction may down-regulate the expression of brain microvascular endothelial tight junction-related proteins PMID: 26884147
  33. These results provide a finely mapped epitope that can be targeted for selective, potent, and non-competitive inhibition of CD73, as well as establish a strategy for inhibiting enzymes that function in both membrane-bound and soluble states. PMID: 26854859
  34. CD73 promotes the growth of human colorectal cancer cells through EGFR and the b-catenin/cyclin D1 signaling pathway. CD73 may be used as a valuable biomarker of colorectal cancer. PMID: 26708311
  35. Our study revealed that CD73 is an independent prognostic factor in prostate cancer. PMID: 26253870
  36. The NT5E gene is involved in both intrinsic and acquired resistance to platinum-based drugs in ovarian cancer. [meta-analysis] PMID: 26629888
  37. CD73 expression was significantly correlated with the invasion into adjacent organs. PMID: 26691441
  38. report on a Chinese family with CALJA and novel compound heterozygous mutations (c.1360G>A (p.Gly454Arg) and c.1387C>T (p.Arg463X)) in NT5E PMID: 26178434
  39. findings reveal that CD73-generated adenosine promotes epithelial integrity and suggest why loss of CD73 in endometrial cancer allows for tumor progression PMID: 26642367
  40. CD73 activity from any host cell type is not required for the monocyte/macrophage polarization in the peritoneum towards a pro- or an anti-inflammatory phenotype in vivo PMID: 26258883
  41. these data suggest a possible role for CD73 and A2A in inflammation observed in patients with T2D and obesity mediated via apoptosis. PMID: 25770019
  42. This study highlights a role for CD73 as a prognostic marker of patient survival and also as a candidate therapeutic target in high-grade serous ovarian cancers. PMID: 26363007
  43. role of CD73 and CD39 ectonucleotidases in T cell differentiation PMID: 26226423
  44. Expression of NPP1 and 5'-nucleotidase by valve interstitial cells promotes the mineralization of the aortic valve through A2aR and a cAMP/PKA/CREB pathway. PMID: 25644539
  45. Although upregulated CD73 expression in tumor cells correlates with a poor prognosis in patients with rectal adenocarcinoma, the combination of CD73 expression in malignant epithelial cells and tumor stroma may have a better prognostic value PMID: 25677906
  46. rs9444348 heterozygosity is associated with increased risk of post-traumatic epilepsy development after brain injury. PMID: 26040919
  47. Species-specific CD73 regulation, with potential significance to cancer, fibrosis, and other diseases characterized by changes in CD73 expression and function. PMID: 25298403
  48. The Nt5e(-/-) targeted mutant mice recapitulate some, but not all, features of ACDC and serve as a model system to study pharmacologic interventions for ectopic mineralization. PMID: 25486201
  49. CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. PMID: 25402681
  50. It decompose ATP and produce adenosine, which regulates immunity via adenosine receptor. PMID: 25675814

Show More

Hide All

Involvement in disease
Calcification of joints and arteries (CALJA)
Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor.
Protein Families
5'-nucleotidase family
Database Links

HGNC: 8021

OMIM: 129190

KEGG: hsa:4907

STRING: 9606.ENSP00000257770

UniGene: Hs.153952

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
How Do You Get Exosomes? A Hands‑On Guide to Isolation, Enrichment, and Quality Control Twice Halted in One Year! Is Akeso's CD73 Monoclonal Antibody in Jeopardy Again? Is PD-1's Golden Partner Still Worth It? Surface Markers of Mesenchymal Stem Cells Identify Treg Cells. You Can Do This. Bispecific Antibody Overview: From Definition to Application Targeting TNFRSF13B: Dual-Target Strategies Usher in New Focus for Treating Tumors and Autoimmune Diseases CUSABIO's Five Expression Systems General Information of Different Tags How to express a protein with bioactivity? How to choose a suitable expression vector? Applications of recombinant proteins Production of Recombinant Protein
Related pathways
Cell markers Target Therapy
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*